Patrick Campbell

Elliot Elias, MD, MPH, provides perspective on recent advances in structural heart disease as well as highlighting the upcoming 40th annual Echocardiography and Structural Heart Symposium at Baptist Health.

Data from the EMPEROR-Reduced trial provide insight into the effects of empagliflozin in patients with heart failure with reduced ejection fraction based on baseline diuretic use from the phase 3 trial.

An analysis of the Phoenix cohort provides insight into responder rates and treatment persistence with infliximab biosimilars among those with no previous exposure to biologics, a previous failure to respond to biologics, or those switching from reference infliximab.

The FDA CRDAC convened on Septemeber 13 to discuss the sNDA for patisiran as a treatment for ATTR-CM, with the meeting concluding in a 9:3 vote in favor of the benefit-risk profile of patisiran.

Use of etanercept biosimilars was not associated with an increased likelihood of treatment discontinuation or disease activity among people with rheumatoid arthritis relative to continuing treatment with originator etanercept.

New data from a dose-finding trial suggests the aldosterone synthase inhibitor lorundrostat could find a role in the management of resistant or uncontrolled hypertension.

An analysis of data from more than 60,000 women details associations between specific chronotypes and risk of unhealthy lifestyle behaviors as well as risk of developing type 2 diabetes.

An analysis of data from more than 20,000 women in the New York City A1c registry details the prevalence of and drivers behind racial/ethnic disparities in the incidence of type 2 diabetes following gestational diabetes mellitus.

At ERS International Congress 2023, new data related to use of sotatercept offered providers additional insight into the effects of the agent in people with PAH.

On September 7, 2023, Alnylam Pharmaceuticals announced positive topline data from the phase 2 KARDIA-1 trial of zilbesiran in the treatment of hypertension.

A case series of 10 patients with newly diagnosed type 1 diabetes provides insight into the beneficial effects of off-label semaglutide use on insulin use, HbA1c, and fasting C-peptide levels among this patient population.

An analysis of CDC data from 1999 to 2020 offers clinicians a snapshot of overall, and race-specific, trends in obesity-related cardiovascular disease deaths since the turn of the century.

A 1-year observational follow-up of a 3-month RCT provides insight into he benefits of advanced hybrid closed-loop system use in people with type 1 diabetes using multiple daily injections and self-monitoring of blood glucose.

The CASTLE-HTx trial provides insight into the effects of catheter ablation in patients with AFib and end-stage heart failure, with potentially practice-changing implications.

Using data from the ASPREE trial, a new study from EASD 2023 suggests use of low-dose aspirin in older adults could reduce the risk of developing type 2 diabetes.

Data from a phase 1 trial in healthy adults indicates muvalaplin, an oral agent, could find a role in lowering Lp(a).

Data from the first of 3 phase 3 trials examing lerodalcibep provide insight into the effects of the once-monthly PCSK9 inhibitor in patients with heterozygous familial hypercholesterolemia.

Outlook Therapeutics announced receipt of the CRL exactly one year after resubmission of their BLA for ONS-5010 as a treatment for wet age-related macular degeneration, which would have been the first indication for a retinal disease given to an ophthalmic version of bevacizumab.

A prespecified analysis of the CLEAR Outcomes trial assessing outcomes according to glycemic status suggests bempedoic acid provided similar relative benefits across the glycemic spectrum, but the greatest absolute benefits were observed in patients with diabetes.

A trio of studies and new guidelines presented at the ESC Congress 2023 highlight advancement in the management of hypertrophic cardiomyopathy, particularly with use of mavacamten.

Results of the 56-week VALOR-HCM trial provide new insight into the effects of mavacamten in patients with highly symptomatic obstructive hypertrophic cardiomyopathy referred for septal reduction therapy.

Results of the FRAIL-AF trial at ESC Congress 2023 provide clinicians with further clarity into the effects of switching from vitamin K antagonists to NOACs in older patients with frailty and atrial fibrillation.

With BridgeBio Pharma Inc. expecting to complete a regulatory submission prior to the close of 2023, the 30-month results of ATTRibute-CM provide the most comprehensive overview yet of the benefit-risk profile for acoramidis in ATTR-CM.

Javed Butler, MD, discusses the overall results of the STEP-HFpEF trial, how he interprets the reduction in adjudicated heart failure events, and how the community's recent experience with SGLT2 inhibitors might inform uptake strategies for semaglutide 2.4 mg.

The largest trial to date, a meta-analysis, and new guideline recommendations have placed a spotlight on the role and benefit of iron supplementation in patients with heart failure and iron deficiency at ESC Congress 2023.

Citing more than half a dozen major trials in the 2 years since the release of their 2021 heart failure guidelines, the European Society of Cardiology has released a focused update to their heart failure guidance.

Results of the STEP-HFpEF trial suggest use of semaglutide 2.4 mg (Wegovy) was associated with improvements in physical symptoms and functional status relative to placebo therapy in adults with HFpEF and obesity.

An analysis of data from more than 30,000 people with type 2 diabetes provides insight into the long-term use of metformin and risk of vitamin B12 deficiency.

A pair of experts in the management of hypertrophic cardiomyopathy provide insight into the recent advances in management and reflect on what these advances have meant for patients.

An analysis of data from CREDENCE provides insight into the prognostic potential of a group of 4 common biomarkers for predicting cardiovascular and kidney issues in people with type 2 diabetes.